16:20-17:15 DEBATE 1 – Interferon alpha should be front line therapy in all ET/PV patients
Chair: Ruben Mesa (San Antonio)
16:20-16:25 Introduction Ruben Mesa (San Antonio)
Audience votes YES or NO
16:25-16:40 Yes Florian Heidel (Greifswald)
16:40-16:55 No Claire Harrison (London)
16:55-17:15 Discussion
Audience votes again YES or NO
17:15-18:25 ROUNDTABLE 1 – Infections in myeloproliferative disorders, including CML
Chair: Ruben Mesa (San Antonio)
17:15-17:20 Introduction Ruben Mesa (San Antonio)
17:20-17:35 COVID-19 and CML Delphine Rea (Paris)
17:35-17:50 COVID-19 in MPN Tiziano Barbui (Bergamo)
17:50-18:05 Infections in MPN - patients survey Florian Heidel (Greifswald)
18:05-18:25 Discussion
18:35-19:35 Simultaneous Meet the Expert sessions:
1. Management of Myelofibrosis & New agents in Srdan Verstovsek (Houston), Ruben Mesa (San Antonio)
Myelofibrosis
2. Clonal Evolution in MPNs Jyoti Nangalia (Hinxton), Ann Mullally (Boston)
3. Management of mastocytosis Jason Gotlib (Stanford), Deepti Radia (London)
4. Transplant for challenging MPNs and CML in 2021 Nicolaus Kröger (Hamburg), Vikas Gupta (Toronto),
Donal McLornan (London)
5. How to safely and successfully use social media in Naveen Pemmaraju (Houston)
medicine
Saturday, February 27th, 2021
09:00-10:00 Simultaneous Meet the Expert sessions:
1. Management of PV & Lessons learned from Heinz Gisslinger (Vienna), Martin Griesshammer (Minden)
Interferon in PV
2. COVID-19 and MPNs Tiziano Barbui (Bergamo), Hugues De Lavallade (London)
3. Investigation and management of erythrocytosis Mary Frances McMullin (Belfast)
4. Investigation and management of eosinophilia Andreas Reiter (Mannheim)
10:00-10:10 Coffee Break and Poster viewing
3
SCIENTIFIC PROGRAMME
SESSION I
OPTIMIZING
CYTOREDUCTION
SESSION II
MANAGEMENT OF CML
WITH TKI
SESSION III
MPN RISK
STRATIFICATION
INCLUDING VASCULAR
EVENTS
DEBATE 1
INTERFERON ALPHA
SHOULD BE FRONT LINE
THERAPY IN ALL ET/PV
PATIENTS
ROUNDTABLE 1
INFECTIONS IN
MYELOPROLIFERATIVE
DISORDERS, INCLUDING
CML
ROUNDTABLE 2
PREGNANCY AND
PARENTING
DEBATE 2
ALLOGENEIC STEM CELL
TRANSPLANTATION
SHOULD BE CONSIDERED
THIRD LINE OPTION IN
CHRONIC PHASE CML
SESSION IV
EVOLVING THERAPIES
IN MYELOFIBROSIS
SESSION V
MANAGEMENT OF
ADVANCED AND UNUSUAL
DISEASE (MPN AND CML)
SESSION VI
TREATMENT FREE
REMISSION IN CML
KEYNOTE LECTURE
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FO R A POSTER
PRESENTATION
DISCLOSURES